Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
This study will assess the benefit of a neuromuscular electrical stimulation device in patients suffering from symptoms and effects of lower limb intermittent claudication.
The circulation of blood around the body is dependent on effective pumping of the heart. Patients with claudication experience pain or discomfort in their legs usually during activity such as walking, which goes away at rest. Claudication is a symptom of peripheral arterial disease (PAD). If left untreated, patients can develop arterial insufficiency which can lead to various complications such as swelling, painful legs, reduced healing of injuries and the loss of limbs in extreme conditions.
PAD can be defined as a narrowing of the arteries reducing blood flow. It is most commonly due to atherosclerosis, and has associations with heart disease, stroke, and diabetes. Its incidence is estimated at 7-14% in the general population, increasing with age to about 20% in the over-seventies. It is associated with effects on mobility, skin condition and quality of life. Symptoms include pain in the legs on walking (intermittent claudication), pain at rest (particularly at night), gangrene, and limb loss. Management of PAD is based on encouraging exercise, and modification of risk factors such as smoking, high blood pressure, high cholesterol and diabetes.
In patients with PAD, exercise tolerance is often limited. Severe symptoms and disease can be treated by procedures such as balloon angioplasty, stenting or surgical bypass, but these procedures have risks. There also remains a percentage of patients who are not suitable for revascularisation, and have few options besides amputation available to them.
Some trials have shown that increasing the blood flow in the legs over time using medical devices (intermittent pneumatic compression, muscle stimulators), in addition to maximal medical and surgical therapy, can increase claudication distance, absolute walking distance, decrease rest pain, and reduce amputation rates. In our unit it has become apparent that there are an increasing number of medical devices available for circulatory support, either for use as an inpatient, out-patient, or a member of the general public. The supporting evidence for these is variable in scientific and clinical content or relevance, and requires clinical trials to evaluate further.
The device being used in this study, activates the pumping action of the leg muscles by providing neuromuscular electrical stimulation (NMES) to cause foot muscle contraction and relaxation. This squeezes blood back towards the heart, improving circulation.
The study will evaluate whether NMES using this device has the same beneficial effects in patients with intermittent claudication.
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Intervention | Experimental | Patients receiving neuromuscular electrical stimulation. |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Neuromuscular Electrical Stimulation | Device | Revitive IX neuromuscular electrical stimulation device will be given to all participants as per protocol. |
|
| Measure | Description | Time Frame |
|---|---|---|
| Change From Baseline in Initial Walking Distance | Initial walking distance measured by treadmill For the initial claudication distance measurement, a fixed load treadmill test will be carried out at 3.5 km/h with a 10% gradient. The initial claudication distance (ICD) is the distance walked until the onset of pain. | Baseline, 6 weeks |
| Absolute Walking Distance Measured by Treadmill | For the absolute claudication distance measurement, a fixed load treadmill test will be carried out at 3.5 km/h with a 10% gradient. The absolute claudication distance (ACD) is the distance walked before the participant is forced to stop due to typical pain. | Change in baseline treadmill walking distance at 6 weeks |
| Measure | Description | Time Frame |
|---|---|---|
| Femoral Haemodynamics Measured by Femoral Artery Duplex Ultrasonography | Ultrasound assessment of blood flow dynamics in the femoral artery will be obtained at rest, and if randomised to the intervention group, whilst using the device. | Change in baseline femoral haemodynamics at 6 weeks |
| Laser Doppler Flow Measured by Optical Laser |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Patients meeting any of the following criteria are to be excluded:
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Alun H Davies, BA BMChB MA | Imperial College London | Study Chair |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Imperial College London - Charing Cross Hospital | London | Hammersmith | W6 8FS | United Kingdom |
| PubMed Identifier | Type | Citation | Retractions |
|---|---|---|---|
| 31912491 | Derived | Babber A, Ravikumar R, Onida S, Lane TRA, Davies AH. Effect of footplate neuromuscular electrical stimulation on functional and quality-of-life parameters in patients with peripheral artery disease: pilot, and subsequent randomized clinical trial. Br J Surg. 2020 Mar;107(4):355-363. doi: 10.1002/bjs.11398. Epub 2020 Jan 7. |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| ID | Title | Description |
|---|---|---|
| FG000 | Intervention | Patients receiving neuromuscular electrical stimulation. Neuromuscular Electrical Stimulation: Revitive IX neuromuscular electrical stimulation device will be given to all participants as per protocol. |
| Title | Milestones | Reasons Not Completed | ||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Overall Study |
|
|
Not provided
Not provided
| ID | Title | Description |
|---|---|---|
| BG000 | Intervention | Patients receiving neuromuscular electrical stimulation. Neuromuscular Electrical Stimulation: Revitive IX neuromuscular electrical stimulation device will be given to all participants as per protocol. |
| Units | Counts |
|---|---|
| Participants |
|
| Title | Description | Population Description | Parameter Type | Dispersion Type | Unit of Measure | Calculate Percentage | Denominator Units Selected | Denominators | Classes |
|---|---|---|---|---|---|---|---|---|---|
| Age, Continuous | Mean |
| Type | Title | Description | Population Description | Reporting Status | Anticipated Posting Date | Parameter Type | Dispersion Type | Unit of Measure | Calculate Percentage | Time Frame | Units Analyzed | Denominator Units Selected | Arm/Group Information | Denominators | Classes | Analyses | ||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Primary | Change From Baseline in Initial Walking Distance | Initial walking distance measured by treadmill For the initial claudication distance measurement, a fixed load treadmill test will be carried out at 3.5 km/h with a 10% gradient. The initial claudication distance (ICD) is the distance walked until the onset of pain. | Posted | Median | Inter-Quartile Range | metres | Baseline, 6 weeks |
|
|
6 weeks - duration of study
Not provided
Not provided
| ID | Title | Description | Deaths (Affected) | Deaths (At Risk) | Serious Events (Affected) | Serious Events (At Risk) | Other Events (Affected) | Other Events (At Risk) |
|---|---|---|---|---|---|---|---|---|
| EG000 | Intervention | Patients receiving neuromuscular electrical stimulation. Neuromuscular Electrical Stimulation: Revitive IX neuromuscular electrical stimulation device will be given to all participants as per protocol. |
Not provided
Not provided
Small scale pilot study.
| Title | Organization | Phone | Extension | |
|---|---|---|---|---|
| Professor Alun Davies, Professor of Vascular Surgery | Imperial College London | +44 (0)20 3311 7309 | a.h.davies@imperial.ac.uk |
Not provided
| ID | Term |
|---|---|
| D007383 | Intermittent Claudication |
| D016491 | Peripheral Vascular Diseases |
| D058729 | Peripheral Arterial Disease |
| C564658 | Peripheral Arterial Occlusive Disease 1 |
| ID | Term |
|---|---|
| D014652 | Vascular Diseases |
| D002318 | Cardiovascular Diseases |
| D012816 | Signs and Symptoms |
| D013568 | Pathological Conditions, Signs and Symptoms |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Optical laser flowmetry probes will be used to assess the superficial skin circulation and temperature. |
| Change in baseline flowmetry at 6 weeks |
| Symptomatic Scores by Questionnaire | Validated questionnaires including the Edinburgh Claudication Questionnaire and Intermittent Claudication Questionnaire will be obtained at baseline and week 6. | Change in baseline questionnaire scores at 6 weeks |
| Quality of Life Scores Measured by Questionnaire | Validated questionnaires including the Euro-Quol 5D and Short Form 36 will be measured at baseline and 6 weeks. | Change in baseline quality of life at 6 weeks |
| Urine Metabolic Profile | A urine sample will be collected at baseline and at 6 weeks. Mass spectroscopy and nuclear magnetic resonance spectroscopy analysis will be carried out. | Change of profile at baseline and at 6 weeks |
| Serum Metabolic Profile | A serum sample will be collected at baseline and at 6 weeks. Mass spectroscopy and nuclear magnetic resonance spectroscopy analysis will be carried out. | Change of profile at baseline and 6 weeks |
| years |
|
| Sex: Female, Male | Count of Participants | Participants |
|
| Region of Enrollment | Number | participants |
|
| Body Mass Index - BMI | Mean | Standard Deviation | kg/m^2 |
|
| Ankle Brachial Pressure Index - ABPI (Right) | The ankle-brachial index test is a quick, noninvasive way to check for peripheral artery disease (PAD). The ankle-brachial index test compares the blood pressure measured at the ankle with the blood pressure measured at the arm. | Mean | Standard Deviation | Ratio |
|
| Ankle Brachial Pressure Index - ABPI (Left) | Mean | Standard Deviation | Ratio |
|
| Initial Claudication Distance - ICD (m) | Median | Inter-Quartile Range | m |
|
| Maximum Claudication Distance - MCD (m) | Median | Inter-Quartile Range | m |
|
| Participants |
|
|
| Primary | Absolute Walking Distance Measured by Treadmill | For the absolute claudication distance measurement, a fixed load treadmill test will be carried out at 3.5 km/h with a 10% gradient. The absolute claudication distance (ACD) is the distance walked before the participant is forced to stop due to typical pain. | Posted | Median | Inter-Quartile Range | m | Change in baseline treadmill walking distance at 6 weeks |
|
|
|
| Secondary | Femoral Haemodynamics Measured by Femoral Artery Duplex Ultrasonography | Ultrasound assessment of blood flow dynamics in the femoral artery will be obtained at rest, and if randomised to the intervention group, whilst using the device. | Not Posted | Change in baseline femoral haemodynamics at 6 weeks | Participants |
| Secondary | Laser Doppler Flow Measured by Optical Laser | Optical laser flowmetry probes will be used to assess the superficial skin circulation and temperature. | Not Posted | Change in baseline flowmetry at 6 weeks | Participants |
| Secondary | Symptomatic Scores by Questionnaire | Validated questionnaires including the Edinburgh Claudication Questionnaire and Intermittent Claudication Questionnaire will be obtained at baseline and week 6. | Not Posted | Change in baseline questionnaire scores at 6 weeks | Participants |
| Secondary | Quality of Life Scores Measured by Questionnaire | Validated questionnaires including the Euro-Quol 5D and Short Form 36 will be measured at baseline and 6 weeks. | Not Posted | Change in baseline quality of life at 6 weeks | Participants |
| Secondary | Urine Metabolic Profile | A urine sample will be collected at baseline and at 6 weeks. Mass spectroscopy and nuclear magnetic resonance spectroscopy analysis will be carried out. | Not Posted | Change of profile at baseline and at 6 weeks | Participants |
| Secondary | Serum Metabolic Profile | A serum sample will be collected at baseline and at 6 weeks. Mass spectroscopy and nuclear magnetic resonance spectroscopy analysis will be carried out. | Not Posted | Change of profile at baseline and 6 weeks | Participants |
| 0 |
| 20 |
| 0 |
| 20 |
| 0 |
| 20 |
Not provided
Not provided
Not provided
| D050197 | Atherosclerosis |
| D001161 | Arteriosclerosis |
| D001157 | Arterial Occlusive Diseases |